PMID- 33942247
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210727
IS  - 1869-6953 (Print)
IS  - 1869-6961 (Electronic)
IS  - 1869-6961 (Linking)
VI  - 12
IP  - 6
DP  - 2021 Jun
TI  - Epidemiology and Economic Burden of Cardiovascular Disease in Patients with Type 
      2 Diabetes Mellitus in Spain: A Systematic Review.
PG  - 1631-1659
LID - 10.1007/s13300-021-01060-8 [doi]
AB  - INTRODUCTION: Cardiovascular disease (CVD) is a leading cause of morbidity and 
      mortality in people with type 2 diabetes mellitus (T2DM). The objectives of this 
      systematic literature review were to identify and synthesize published data 
      describing the epidemiology and mortality of CVD in the T2DM population and the 
      associated economic burden. METHODS: We conducted a systematic review searching 
      the PubMed and MEDES databases from 2009 to 2019 using predefined selection 
      criteria. Peer-reviewed observational studies reporting primary or secondary data 
      on CVD prevalence, incidence, mortality, resource use and costs in patients with 
      T2DM in Spain, written in English and Spanish, were included. Data were tabulated 
      and summarized descriptively. RESULTS: Of 706 articles identified, 52 were 
      included in the review. Most studies were based on data from hospital discharge 
      databases and registries. The reported prevalence of CVD among patients with T2DM 
      ranged from 6.9 to 40.8%. The prevalence of coronary heart disease ranged from 
      4.7 to 37%, stroke from 3.5 to 19.6%, peripheral artery disease from 2.5 to 
      13.0%, and heart failure from 4.3 to 20.1%. In-hospital CVD mortality rates 
      ranged from 5.6 to 10.8%. Direct costs due to CVD in hospitalized patients with 
      T2DM were increased (> 50%) compared with patients without CVD. No studies 
      analysed indirect costs of CVD in patients with T2DM. CONCLUSIONS: The burden of 
      CVD among patients with T2DM, combined with the elevated costs of care, 
      highlights the importance of early prevention as part of integrated management of 
      the disease to improve clinical and economic outcomes.
FAU - Artime, Esther
AU  - Artime E
AD  - Eli Lilly and Company, Avda. de la Industria 30, Alcobendas, 28108, Madrid, 
      Spain. artime_esther@lilly.com.
FAU - Romera, Irene
AU  - Romera I
AD  - Eli Lilly and Company, Avda. de la Industria 30, Alcobendas, 28108, Madrid, 
      Spain.
FAU - Diaz-Cerezo, Silvia
AU  - Diaz-Cerezo S
AD  - Eli Lilly and Company, Avda. de la Industria 30, Alcobendas, 28108, Madrid, 
      Spain.
FAU - Delgado, Elias
AU  - Delgado E
AD  - Department of Endocrinology and Nutrition, University of Oviedo, Oviedo, Spain.
AD  - Central University Hospital of Asturias, Oviedo, Spain.
AD  - Health Research Institute of the Principality of Asturias (ISPA), Oviedo, Spain.
AD  - Spanish Biomedical Research Network in Rare Diseases, Madrid, Spain.
LA  - eng
GR  - The study was funded by Eli Lilly and Company/Eli Lilly and Company/
PT  - Journal Article
PT  - Review
DEP - 20210503
PL  - United States
TA  - Diabetes Ther
JT  - Diabetes therapy : research, treatment and education of diabetes and related 
      disorders
JID - 101539025
PMC - PMC8179862
OTO - NOTNLM
OT  - Burden of disease
OT  - Cardiovascular disease
OT  - Costs
OT  - Diabetes mellitus, type 2
OT  - Incidence
OT  - Mortality
OT  - Prevalence
EDAT- 2021/05/05 06:00
MHDA- 2021/05/05 06:01
PMCR- 2021/05/03
CRDT- 2021/05/04 07:01
PHST- 2021/02/17 00:00 [received]
PHST- 2021/04/12 00:00 [accepted]
PHST- 2021/05/05 06:00 [pubmed]
PHST- 2021/05/05 06:01 [medline]
PHST- 2021/05/04 07:01 [entrez]
PHST- 2021/05/03 00:00 [pmc-release]
AID - 10.1007/s13300-021-01060-8 [pii]
AID - 1060 [pii]
AID - 10.1007/s13300-021-01060-8 [doi]
PST - ppublish
SO  - Diabetes Ther. 2021 Jun;12(6):1631-1659. doi: 10.1007/s13300-021-01060-8. Epub 
      2021 May 3.